Showing results (391-400 of 491) with videos related to
Sort By:
Pageof 50
The New England Journal of Medicine|August 12, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationManesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, et al.Journal of the American College of Cardiology|July 7, 2012
An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trialsMichelle L O'Donoghue, Ajay Vaidya, Rizwan Afsal, et al.American Heart Journal|September 21, 2015
Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trialJose Carlos Nicolau, Deepak L Bhatt, Matthew T Roe, et al.American Heart Journal|April 30, 2017
Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndromeConnie N Hess, Robert M Clare, Megan L Neely, et al.JAMA Network Open|February 27, 2020
Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial FibrillationKeith A A Fox, Priscilla Velentgas, A John Camm, et al.Journal of the American College of Cardiology|January 19, 2019
Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG StudyAndre Lamy, John Eikelboom, Tej Sheth, et al.Journal of the American College of Cardiology|February 9, 2013
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Manesh R Patel, Anne S Hellkamp, Yuliya Lokhnygina, et al.European Heart Journal|November 30, 2017
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registryArthur Darmon, Deepak L Bhatt, Yedid Elbez, et al.European Heart Journal|July 1, 2016
Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AFJean-Pierre Bassand, Gabriele Accetta, Alan John Camm, et al.Journal of Thrombosis and Haemostasis : JTH|June 1, 2021
Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF RegistryFrank Cools, Dana Johnson, Alan J Camm, et al.Pageof 50